Trial Profile
Cost of Treatment of Chronic Hepatitis C Using Combination of Peginterferon alfa-2b Plus Ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 11 Nov 2011 Patient numbers amended from 913 to 901 as reported by ClinicalTrials.gov.
- 28 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.